Dr Atkins has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Prior to joining Congenica, Dr Atkins was CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. Past roles also include global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. Dr Atkins also has over 20 years’ experience with Johnson & Johnson’s Medical Device and Diagnostic businesses in R&D and business development and in senior international commercial roles.

Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, and has over 25 years of research experience in human molecular genetics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and is a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.

Pierre is an early stage technology investor with a current investment focus on digital health, medical technologies, cybersecurity and machine learning / AI. He is a non-executive director on the boards of Inotec, Repositive, Doctify, Congenica and oversees investments in PhoreMost, Organox and Antidote (formerly TrialReach).

Pierre brings operational experience to the portfolios, having grown several life science businesses in Asia and Europe. Pierre started his career as an auditor with KPMG in France and subsequently worked as a financial engineer at Natixis and as a research fellow in health and urban microeconomics.

Matt is Senior Group Leader at the Wellcome Trust Sanger Institute and a leader in the Deciphering Developmental Disorders, 1000 Genomes and UK10K projects. He has pioneered the analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods, and has led an initiative to characterise structural variation in the human genome, and integrate this knowledge into disease and population genetic studies. Matt has been awarded the Balfour Lecture by the Genetics Society and the Crick Lecture prize for accomplishments in genetics by the Royal Society.

Richard is a Group Leader of the Human Genetics Programme at the Wellcome Trust Sanger Institute, a Fellow of the Royal Society, and a Member of EMBO. A pioneer in the industry, he has developed sequence data analysis tools that are now standards in the field. His current research focuses on human genetic variation by large scale genome-wide re-sequencing. Richard has led the international 1000 Genomes Project and the UK10K Genome Project, and has made significant contributions to the Ensembl resource for vertebrate genome annotation, and the TreeFam and Pfam databases.

Phil is a consultant physician and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, an Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalised Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.